Please login to the form below

Not currently logged in
Email:
Password:

Profil Institute appoints former Amylin CEO

Dan Bradbury joins board of diabetes company

The Profil Institute for Clinical Research has appointed Dan Bradbury to its board of directors.

Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.

He is currently a managing member of the life sciences consultancy firm BioBrit.

Dr Marcus Hompesch, CEO of diabetes-focused Profil Institute said: “Dan Bradbury is a highly regarded and prominent leader in the global pharmaceutical industry.”

He added: “With Mr Bradbury's considerable experience in driving strategic growth, I am certain that he will bring tremendous insight and guidance to help further shape the company's strategic course.”

7th November 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...